The Aerosurf Phase 2 trial involved 341 premature infants receiving nasal continuous positive airway pressure (nCPAP) for RDS and was designed to evaluate the safety, tolerability and potential ...

Windtree Therapeutics' roots may have received some urgently needed financial watering last month thanks to a private placement of its stock, but the biotech still doesn’t have enough money to keep ...

WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company ...

WindTree Therapeutics has the clinical results it wants—but is missing the bull market, meaning the biotech is exploring strategic options. Amid the market downturn, the biotech is considering a ...

WARRINGTON, Pa., July 1, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute ...

WARRINGTON, Pa., March 31, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced major reductions in its outstanding Series C and Series D preferred shares, positioning the company to limit future equity ...

Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading higher by 36.5% to $2.03 during Monday’s session after the company regained compliance with Nasdaq’s minimum bid price requirement, ensuring ...

WARRINGTON, Pa., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a ...